AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...

The T4 and T4A reporting requirements for employer- and payer-offered dental benefits, for issuers who would otherwise enter code 1, are waived again for 2024. This Canadian Dental Care Plan (CDCP) ...

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Recent Market Developments .October 28, 2024: AbbVie announced its acquisition of Aliada Therapeutics, strengthening its neuroscience portfolio and enhancing its focus on Alzheimer's disease.

as well as expanding its portfolio of product candidates due to the acquisition of Aliada Therapeutics at the end of October 2024 and Cerevel Therapeutics. Ultimately, due to the anticipated ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...